Zyversa Therapeutics Inc
NASDAQ:ZVSA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.26
32.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ZVSA stock under the Base Case scenario is 3.05 USD. Compared to the current market price of 1.26 USD, Zyversa Therapeutics Inc is Undervalued by 59%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Zyversa Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ZVSA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Zyversa Therapeutics Inc
Balance Sheet Decomposition
Zyversa Therapeutics Inc
Current Assets | 641.4k |
Cash & Short-Term Investments | 119.5k |
Other Current Assets | 521.9k |
Non-Current Assets | 18.8m |
PP&E | 1.7k |
Intangibles | 18.6m |
Other Non-Current Assets | 178.5k |
Current Liabilities | 10m |
Accounts Payable | 8.3m |
Accrued Liabilities | 1.7m |
Non-Current Liabilities | 854.6k |
Other Non-Current Liabilities | 854.6k |
Earnings Waterfall
Zyversa Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-22.4m
USD
|
Operating Income
|
-22.4m
USD
|
Other Expenses
|
554k
USD
|
Net Income
|
-21.9m
USD
|
Free Cash Flow Analysis
Zyversa Therapeutics Inc
USD | |
Free Cash Flow | USD |
ZVSA Profitability Score
Profitability Due Diligence
Zyversa Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Zyversa Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
ZVSA Solvency Score
Solvency Due Diligence
Zyversa Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Zyversa Therapeutics Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZVSA Price Targets Summary
Zyversa Therapeutics Inc
Dividends
Current shareholder yield for ZVSA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida. The company went IPO on 2021-12-21. The firm is focused on leveraging advanced technologies to develop drugs for patients with renal or inflammatory diseases. The Company’s development pipeline includes renal drug candidate, namely VAR 200, (2-hydroxypropyl-beta-cyclodextrin or 2HPβCD), a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. Its VAR 200 has potential to treat other glomerular diseases, including alport syndrome and diabetic kidney disease. The firm's development pipeline also includes anti-inflammatory drug candidate, namely IC 100, an inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases. Its phase 2a renal product candidate, VAR 200, which mediates removal of excess intracellular lipids that contribute to kidney damage leading to end-stage renal disease.
Contact
IPO
Employees
Officers
The intrinsic value of one ZVSA stock under the Base Case scenario is 3.05 USD.
Compared to the current market price of 1.26 USD, Zyversa Therapeutics Inc is Undervalued by 59%.